Haemonetics
296 hedge funds and large institutions have $4.55B invested in Haemonetics in 2023 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 97 increasing their positions, 123 reducing their positions, and 35 closing their positions.
699% more call options, than puts
Call options by funds: $18M | Put options by funds: $2.25M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6% more capital invested
Capital invested by funds: $4.3B → $4.55B (+$247M)
6% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 35
0.08% more ownership
Funds ownership: 99.95% → 100.03% (+0.08%)
0% more funds holding
Funds holding: 296 → 296 (0)
21% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 123
Top Buyers
Top Sellers
HAE Hedge Fund Activity: Q3 2023 in Review
296 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2023, worth a combined $4.55B — up 5.7% from $4.3B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new HAE positions and 35 closed out — a net gain of 2 holders — while 97 added to existing stakes and 123 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $75.6M. The largest seller was Arrowstreet Capital, cutting an estimated $38.9M.
- 296 institutional investors held Haemonetics (HAE) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $4.55B of Haemonetics stock for Q3 2023, up 5.7% quarter-over-quarter.
- 37 funds opened new Haemonetics positions in Q3 2023 and 35 closed out, a net change of +2 holders.
- The largest Haemonetics buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $75.6M added.
- The largest Haemonetics seller in Q3 2023 was Arrowstreet Capital, an estimated $38.9M sold.
Based on aggregated 13F filings for Q3 2023.